Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the <i>All of Us Research Program</i> Cohort
Our results show that HT-associated cardiovascular risk may be synergistically amplified by dyslipidemia. These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors.
Authors
- Yuanchu James Yang (ORCID: https://orcid.org/0000-0003-1518-1505)
- Tam C. Tran
- Chenjie Zeng (ORCID: https://orcid.org/0000-0002-0149-5661)
- Peter J. Sauer
- Joshua C. Denny (ORCID: https://orcid.org/0000-0002-3049-7332)
- Kerry Schaffer (ORCID: https://orcid.org/0000-0002-0097-1574)
- Ben Ho Park (ORCID: https://orcid.org/0000-0001-8119-2291)
- Lincoln A. Brown
Institutions
- National Institutes of Health (US)
- Vanderbilt University (US)
- National Human Genome Research Institute (US)
- Office of the Director (US)
- National Institutes of Health Clinical Center (US)
- Vanderbilt-Ingram Cancer Center
Publication Details
- Journal
- The Prostate
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1002/pros.24913
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Human Genome Research Institute